.
Clinicians frequently switch treatment to a second TNFi agent when patients do not achieve an adequate response [9] [10] [11] , lose their initial response [12] , or experience adverse events with their first course of a TNFi agent [13, 14] .
The use of TNFi agents for the treatment of RA is associated with significant costs, estimated to be between $14,000 and $22,000 annually [4, 5] , especially for patients who require dose escalation to achieve or maintain a clinical response, which entails 2-44% higher costs compared with non-dose escalating patients [15] [16] [17] . Additionally, RA is a chronic disease for which treatment-free remission is rare and thus requires long-term therapy, adding to the lifetime cost of treatment. Evaluation of treatment patterns and associated costs is important for clinicians to make informed treatment decisions and for payers to manage costs; this evaluation is also important specifically among US veterans with RA because such an assessment has never been conducted in this population. Therefore, we evaluated clinical outcomes and associated costs in US veterans with RA enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry who initiated TNFi therapy after VA enrollment. This analysis compared disease activity and drug costs in patients treated with TNFi agents as a class, rather than comparing specific agents. The comparison determined differences between patients who were persistent on a single TNFi agent and patients who interrupted therapy with a single TNFi agent or switched to a different TNFi agent.
Patients were specifically evaluated on duration of treatment, clinical response, rate of switching, and drug costs associated with the initial TNFi treatment episode as well as subsequent treatment episodes within the VA health care system.
METHODS
The VARA Registry 
Data Sources
Three administrative VA databases [21] were used in the analysis, including the Corporate Data Warehouse (CDW) [22] , Decision Support System (DSS) National Pharmacy Extract [23] , and Pharmacy Benefits Management (PBM)
database [24] . Descriptions of these databases have been previously presented [25] . The Veterans Health Administration structured pharmacy data do not completely capture the dispensing of outpatient drug infusion data.
Furthermore, the barcode medication administration data only capture medications administered to inpatients. Therefore, we conducted a chart review of VA electronic medical records over the study period to determine administration of infliximab through nurse infusion notes. Because some inconsistencies in the outpatient pharmacy dispensing data were observed for adalimumab and etanercept, we developed an algorithm that integrated information from the three databases (CDW, DSS, and PBM) and defined each treatment episode for each patient. The algorithm reconciled differences between databases by using information from all data sources as well as comparing treatment patterns before and after the discrepancies to estimate correct dosing [25] . For patients with evidence of any infliximab infusion from CDW (outpatient pharmacy, inpatient unit dose, or IV package), DSS, or PBM, a complete individual patient medical record review was completed by trained chart abstractors over the study period to characterize infliximab administration events during the study period.
Study Outcomes
Each dispensing or administration event of a TNFi agent was used along with information on quantity dispensed and days supply to construct individual treatment episodes. 
Statistical Analysis
Continuous data are presented as means and 95% confidence intervals (CIs), and dichotomous data are presented as proportions and 95% CIs. The focus on CIs instead of P values provides evidence for the stability of estimates along with statistical significance testing-when the CIs do not overlap between two groups then the P values are \0.05 and considered significantly different [27, 28] .
The data analysis for this paper was generated using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). part of an analysis of persistence and dose escalation was previously described [25] . Of these, 262 patients remained on their initial TNFi agent during the entire observation period (single therapy), 142 had a gap of 90 or more days in therapy and started a second course on their initial TNFi (interrupted therapy), and 159 started a second course with a different TNFi (switched therapy) (Fig. 1) . The study population was predominantly male and white (Table 1) . Baseline demographic and clinical characteristics were similar among patients with single therapy, interrupted therapy, and switched therapy. The initial TNFi agents selected are listed in Table 1 .
Average Duration of Drug Courses
The mean duration of single therapy was 34.3 months, which was similar to the combined mean duration of the first and In all groups, post-treatment DAS28 was significantly lower than DAS28 before starting TNFi therapy (Table 3) . Patients who switched to a different TNFi for their second course of treatment had higher mean DAS28 before initiating TNFi therapy compared with patients who received single therapy or interrupted therapy: patients who remained on a single TNFi agent whether they underwent single or interrupted therapy had a pretreatment DAS28 score of 4.53 or 4.56, respectively, while those who switched had a pretreatment DAS28 score of 5.3 (Fig. 2) . The change in DAS28 from pre-to post-treatment TNFi tumor necrosis factor inhibitor, CI confidence interval, NA not applicable Mean difference in DAS28 from pre-treatment to C90 days after first course (95% CI)
Mean difference in DAS28 during initial course to C90 days after second course (95% CI)
DAS28 Disease activity score based on 28 joints, TNFi tumor necrosis factor inhibitor, CI confidence interval, NA not applicable was similar among patients who remained on their initial TNFi, restarted their initial TNFi, and switched TNFi ( Fig. 2 ; Table 3 ).
Consequently, patients with switched therapy had higher post-treatment DAS28 than patients with single therapy and interrupted therapy (Fig. 2) . Responders and non-responders were included in the analysis, which reduced the mean improvement in DAS28 (Table 3) .
Cost of Treatment
Mean annualized costs for drug and drug administration for the first course of treatment were similar among patients who remained on their initial TNFi, patients who restarted their initial TNFi, and patients who switched TNFi ( rates of 12-25% for interrupted therapy with a single TNFi agent during the first year of TNFi therapy based on a 45-day gap in treatment [9] , which was similar to the 25% rate of interruption in our patients based on a 90-day gap in treatment; however, their switching rate was 13%, which was lower than our observed switching rate of 28%. Scrivo et al. reported a 10% switching rate [29] both observed a 13% switching rate [11, 30] over a mean of 15 months, and Virkki et al.
found a 37% switching rate [12] over a mean of 28 months. Schabert et al. reported a low switching rate of 9-11% in the first year of treatment [5] .
Comparison of our results with those of other groups who have reported significant clinical improvement in disease severity when switching TNFi agents is challenging because of the differences in methodology and clinical settings for these studies. Many of these comparative studies do not have baseline disease activity assessment during the first TNFi course. Instead, these analyses compare the response during the second course of TNFi treatment to a clinical course during the first course of TNFi treatment [13, 31, 32] . Others have reported similar responses with a first and second TNFi agent with increases in disease activity in between courses [33] . In some cases, high persistence rates (71-74%) on second TNFi agents are reported, but without disease severity measures [30] . A separate report of US veterans switching biologics demonstrated that veterans who switched had a higher DAS28 score before TNFi therapy than veterans who did not switch [14] . Virkki et al. and Scrivo et al. emphasized the benefit of switching TNFi agents when a secondary loss of efficacy was seen [12, 29] . In our analysis, the change in clinical response TNFi tumor necrosis factor inhibitor, USD United States dollars, CI confidence interval, NA not applicable with the second TNFi agent from initial baseline was similar to the response with the initial TNFi agent. The disease activity during the first and second courses was similar. This observation may have represented clinical benefit until the secondary loss of efficacy occurred. There is speculation that the development of anti-TNFi antibodies may play a potential role in these cases with secondary loss of efficacy [9] .
Another goal of our analysis was to compare costs of TNFi therapy within a drug class between patients who used a single TNFi agent and patients who switched TNFi agents. This work demonstrates that, while the annualized drug costs of the first course of treatment for patients who switched TNFi therapy were slightly higher than the costs of the first course of treatment in patients who remained on a single TNFi agent, these cost differences were not statistically significant. The annualized costs for patients with interrupted therapy with a single TNFi agent were similar for the first and second courses of treatment. In contrast, the costs for the second course of TNFi treatment in patients who switched to a second TNFi agent were significantly higher than those for the second course of treatment in patients who had interrupted therapy with a single TNFi agent. Differences in cost may have been the result, in part, of differences in disease activity, which required dose escalation to address this higher disease activity. The higher costs for second courses of medication may have been related to dose escalation during the second course of treatment, which has been previously reported [15] .
While the use of biologic agents is associated with significant costs, most analyses report that these agents fall within a currently accepted threshold of cost effectiveness [34] [35] [36] [37] . Prior studies have specifically focused on costs per agent rather than costs of the TNFi therapy class.
These studies have generally demonstrated that costs for infliximab are higher than those for injectable agents [4, 5, [38] [39] [40] . We have previously published that dose escalation is more common with infliximab in subsequent courses, which is also associated with higher costs [25] .
Strengths of our study included rheumatologist-confirmed diagnosis of RA in contrast to the use of administrative data in many other studies, the wide geographic distribution of patients across the US, the collection of baseline and post-treatment disease severity information using the DAS28, and standardized medical records and administrative databases within the VA system across all participating sites. Veterans enrolled in VA care have access to TNFi therapy as needed.
Limitations of the study included a predominance of men with RA of long-term duration reflecting the US veteran population, which may limit the generalizability of these findings to other populations. This study population of US Veterans is principally male and elderly in comparison with most RA populations that are predominantly female and of younger age. 
